当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).

Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath).

Abstract：

:Infectious complications due to adenovirus are of increasing concern after allogeneic stem cell transplantation. Over the past 4 years, we have modified our conditioning regimens to use alemtuzumab in preference to anti-thymocyte globulin (ATG) for pediatric patients receiving stem cell transplants from alternate donors. Recent reports in adult studies implicate alemtuzumab as a risk factor for adenovirus infection. We therefore evaluated the incidence of adenovirus infection in pediatric patients receiving either ATG or alemtuzumab in their conditioning regimens. Of the 111 patients evaluated, a total of 54 patients received ATG and 57 patients received alemtuzumab. In total, 35/111 (32%) patients were infected by adenovirus, and 9/111 (8%) had adenovirus disease (AD). Adenovirus infection was greater in the alemtuzumab group than the ATG group (23/57 vs 12/54) (P=0.039) and disseminated AD was more frequent in the alemtuzumab group vs the ATG group (8/57 and 1/54 respectively) (P=0.032). The presence of Grade 3-4 graft-versus-host disease was a risk factor for adenovirus infection. Our findings highlight the fact that adenovirus infection is a frequent complication after stem cell transplantation from alternate donors in the pediatric population and that alemtuzumab increases the risk of infection compared to ATG. This work will help in identifying at-risk populations for our upcoming immunotherapy trial using adoptively transferred donor-derived adenovirus-specific cytotoxic T lymphocytes.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Myers GD,Krance RA,Weiss H,Kuehnle I,Demmler G,Heslop HE,Bollard CM

doi

10.1038/sj.bmt.1705164

subject

Has Abstract

pub_date

2005-12-01 00:00:00

pages

1001-8

issue

11

eissn

0268-3369

issn

1476-5365

pii

1705164

journal_volume

36

pub_type

杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Secondary solid tumors after allogeneic hematopoietic SCT in Japan.

    abstract：:To evaluate the incidence and risk factors for secondary solid tumors in Japan after allogeneic hematopoietic SCT (allo-HSCT), 2062 patients who had received allo-HSCT between 1984 and 2005 were retrospectively analyzed. Twenty-eight patients who developed 30 solid tumors were identified a median of 5.6 years after tr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/bmt.2011.23

    authors： Yokota A,Ozawa S,Masanori T,Akiyama H,Ohshima K,Kanda Y,Takahashi S,Mori T,Nakaseko C,Onoda M,Kishi K,Doki N,Aotsuka N,Kanamori H,Maruta A,Sakamaki H,Okamoto S,Kanto Study Group for Cell Therapy (KSGCT).

    更新日期：2012-01-01 00:00:00

  • Therapeutic effect of umbilical cord serum eyedrops for the treatment of dry eye associated with graft-versus-host disease.

    abstract：:This study was performed to investigate the therapeutic effect of umbilical cord serum eyedrops on dry eye associated with graft-versus-host disease (GVHD). Twenty-four eyes of 12 patients with severe dry eye syndrome associated with GVHD were treated with 20% umbilical cord serum eyedrops. Symptom scoring, corneal se...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1705566

    authors： Yoon KC,Jeong IY,Im SK,Park YG,Kim HJ,Choi J

    更新日期：2007-02-01 00:00:00

  • A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies.

    abstract：:Since approximately 30% of leukemia patients relapse after allogeneic BMT using total body irradiation (TBI)-based preparative regimens, treatment intensity may be suboptimal. The killing of leukemia cells is proportional to the radiation absorbed dose. We studied the feasibility and toxicity of escalating the doses o...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1702230

    authors： Sobecks RM,Daugherty CK,Hallahan DE,Laport GF,Wagner ND,Larson RA

    更新日期：2000-04-01 00:00:00

  • Gene therapy of chronic granulomatous disease.

    abstract：:Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder which results from absence or malfunction of the respiratory burst oxidase normally expressed in neutrophils and other phagocytic leukocytes. Two-thirds of the patients are males hemizygous for mutations in the X-linked gene coding for gp91-pho...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702365

    authors： Grez M,Becker S,Saulnier S,Knöss H,Ott MG,Maurer A,Dinauer MC,Hoelzer D,Seger R,Hossle JP

    更新日期：2000-05-01 00:00:00

  • Quality of life and psychological distress of bone marrow transplant recipients: the 'time trajectory' to recovery over the first year.

    abstract：:The purpose of this study was to measure the trajectory of psychosocial recovery over the first year after bone marrow transplantation (BMT). BMT patients were assessed at baseline (n = 86), hospital discharge (n = 74), 100 days (n = 64) and at 1 year (n = 45). Participants completed the Functional Assessment of Cance...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1701115

    authors： McQuellon RP,Russell GB,Rambo TD,Craven BL,Radford J,Perry JJ,Cruz J,Hurd DD

    更新日期：1998-03-01 00:00:00

  • Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s.

    abstract：:There is substantial progress in preventing and treating cytomegalovirus (CMV) infections and CMV-related disease after allogeneic bone marrow transplantation. In CMV-seronegative recipients, use of CMV-seronegative blood products eliminates most CMV infections. Effective prophylaxis for CMV-seropositive recipients is...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Winston DJ,Gale RP

    更新日期：1991-07-01 00:00:00

  • Campylobacter jejuni bacteremia and Guillain-Barré syndrome in a patient with GVHD after allogeneic BMT.

    abstract：:Guillain-Barré syndrome is a rare neurologic complication after allogeneic BMT. In the non-transplant setting, Guillain-Barré syndrome has typically been associated with antecedent acute infections and numerous reports have suggested an association between Campylobacter jejuni infection and the subsequent development ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Hagensee ME,Benyunes M,Miller JA,Spach DH

    更新日期：1994-03-01 00:00:00

  • Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic stem cell transplantation.

    abstract：:Bloodstream infection (BSI) is a significant complication following allogeneic hematopoietic stem cell transplantation (allo-SCT). Corticosteroids mask inflammatory responses, delaying the initiation of antibiotics. We reviewed medical records of 69 allo-SCT patients who had been on >0.5 mg/kg prednisolone to investig...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704830

    authors： Chizuka A,Kami M,Kanda Y,Murashige N,Kishi Y,Hamaki T,Kim SW,Hori A,Kojima R,Mori SI,Tanosaki R,Gomi H,Takaue Y

    更新日期：2005-03-01 00:00:00

  • Assessment of TREC, KREC and telomere length in long-term survivors after allogeneic HSCT: the role of GvHD and graft source and evidence for telomere homeostasis in young recipients.

    abstract：:Reconstitution of the adaptive immune system following allogeneic hematopoietic stem cell transplantation is crucial for beneficial outcome and is affected by several factors, such as GvHD and graft source. The impact of these factors on immune reconstitution has been thoroughly investigated during the early phase aft...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2017.216

    authors： Gaballa A,Norberg A,Stikvoort A,Mattsson J,Sundberg B,Uzunel M,Remberger M,Uhlin M

    更新日期：2018-01-01 00:00:00

  • Bone marrow transplantation from unrelated donors: the Italian experience. GITMO, AIEOP and IBMDR.

    abstract：:We report on 24 patients with leukemia (19 pts), congenital disorders (4 pts) or severe aplastic anemia (1 pt) who received bone marrow transplantation from unrelated volunteer donors in 8 Italian Institutions. All the donor/recipient pairs were serologically HLA-A,B,DR matched; MLR was non reactive in 21 out of 24 ca...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Lanino E,Lamparelli T,Dini G,Alessandrino EP,Aversa F,Calori E,Medugno D,Garbarino L,Locatelli F,Marenco P

    更新日期：1993-01-01 00:00:00

  • Low T3-syndrome and nutritional status as prognostic factors in patients undergoing bone marrow transplantation.

    abstract：:Bone marrow transplantation is known to be associated with considerable morbidity and mortality. The aim of this study was to determine the influence of nutritional status and development of sick euthyroid syndrome as prognostic factors for outcome after BMT. In 100 patients who underwent transplantation the following...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701502

    authors： Schulte C,Reinhardt W,Beelen D,Mann K,Schaefer U

    更新日期：1998-12-01 00:00:00

  • In pursuit of the allo-immune response in multiple myeloma: where do we go from here?

    abstract：:AlloSCT is a potentially curative procedure for haematological malignancies and marrow failure syndromes. However, unlike leukaemia and lymphoproliferative disorders, AlloSCT has yet to find its place in the clinical management of patients with multiple myeloma. AlloSCT in multiple myeloma is associated with a high pr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2008.397

    authors： Cook G,Bird JM,Marks DI

    更新日期：2009-01-01 00:00:00

  • Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

    abstract：:Thirty patients, with high-risk acute myeloid leukemia (AML, n = 20) or myelodysplastic syndrome (MDS, n = 10), were enrolled in a phase II trial entailing prophylactic post-transplant azacitidine (AZA) plus escalated doses of donor lymphocyte infusion (DLI). The median number of AZA cycles was 5 (1-12) with 10 patien...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41409-019-0536-y

    authors： Guillaume T,Malard F,Magro L,Labopin M,Tabrizi R,Borel C,Chevallier P,Vigouroux S,Peterlin P,Garnier A,Rubio MT,Huynh A,Milpied N,Moreau P,Gaugler B,Yakoub-Agha I,Mohty M

    更新日期：2019-11-01 00:00:00

  • Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b.

    abstract：:A patient with acute myeloid leukemia secondary to therapy of choriocarcinoma underwent T cell non-depleted allogeneic bone marrow transplantation from an unrelated donor in first untreated relapse. Persistent/relapsed leukemia 4 months after transplantation did not respond to cessation of cyclosporine. Due to logisti...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700793

    authors： Singhal S,Powles R,Treleaven J,Mehta J

    更新日期：1997-06-01 00:00:00

  • Pregnancy after bone marrow transplantation for severe aplastic anemia.

    abstract：:Two women suffering from severe aplastic anemia were treated by bone marrow transplantation (BMT). They became pregnant 17 and 40 months after the procedure. During the first 20 weeks of pregnancy, one of them continued to receive cyclosporin A (CSA) to prevent graft-versus-host disease. Her CSA serum levels during th...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Schmidt H,Ehninger G,Dopfer R,Waller HD

    更新日期：1987-10-01 00:00:00

  • Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.

    abstract：:The management of acute leukaemia which relapses following an allogeneic stem cell transplant remains a major challenge. In this review we summarize the outcomes of the currently available treatment modalities and discuss emerging novel approaches. ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1705888

    authors： Shaw BE,Russell NH

    更新日期：2008-03-01 00:00:00

  • Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.

    abstract：:Leukemic relapse remains the most frequent reason for treatment failure in patients with acute myeloblastic leukemia (AML) treated with autologous blood stem cell transplantation (ABSCT). The aim of this study was to evaluate the possible role of autologous bone marrow transplant (ABMT) in patients with AML who relaps...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： de la Rubia J,Sanz GF,Martín G,Sempere A,Picón I,Carral A,Larrea L,Martínez J,Soler MA,Bonanad S,López F,Jarque I,Sanz MA

    更新日期：1996-12-01 00:00:00

  • A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation.

    abstract：:In an otherwise eligible patient with relapsed lymphoma, inadequate mobilization of hematopoietic stem cells (HSCs) is a limiting factor to proceeding with an autologous hematopoietic cell transplantation (auto-HCT). Multiple strategies have been used to mobilize an adequate number of HSCs with no obvious front-line s...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2016.304

    authors： Haverkos BM,Huang Y,Elder P,O'Donnell L,Scholl D,Whittaker B,Vasu S,Penza S,Andritsos LA,Devine SM,Jaglowski SM

    更新日期：2017-04-01 00:00:00

  • Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.

    abstract：:The treatment of established veno-occlusive disease (VOD) of the liver with tissue plasminogen activator (tPA) has been disappointing. In attempts to improve upon these results we identified a subgroup of patients with consistently elevated bilirubin levels who did not meet conventional criteria for VOD (Susp VOD) but...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1702069

    authors： Schriber J,Milk B,Shaw D,Christiansen N,Baer M,Slack J,Tezcan H,Wetzler M,Herzig G

    更新日期：1999-12-01 00:00:00

  • High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis.

    abstract：:High-dose immunoablative chemotherapy with autologous haematopoietic cell support might be beneficial in the treatment of intractable forms of MS. We mobilised PBPC in 11 patients with secondary progressive MS and finally eight patients were grafted after high-dose BEAM chemotherapy with either in vitro or in vivo T c...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/sj.bmt.1702180

    authors： Kozák T,Havrdová E,Pit'ha J,Gregora E,Pytlík R,Maaloufová J,Marecková H,Kobylka P,Vodvárková S

    更新日期：2000-03-01 00:00:00

  • Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: results of a phase I-II clinical trial.

    abstract：:Suboptimal neutrophil and platelet recovery after unrelated donor umbilical cord blood transplantation (UCBT) may be due in part to an impaired microenvironment after intensive chemoradiotherapy. In an attempt to speed hematopoietic recovery, 15 pediatric patients with high-risk acute leukemia were enrolled on a singl...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.348

    authors： Macmillan ML,Blazar BR,DeFor TE,Wagner JE

    更新日期：2009-03-01 00:00:00

  • Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience.

    abstract：:Between May 1994 and May 2000, we autotransplanted 48 consecutive patients, 21 females and 27 males aged over 60 years (range: 60-78, median: 63). Sixteen patients had multiple myeloma (MM), 14 high-grade non-Hodgkin's lymphoma (HGNHL), six low-grade non-Hodgkin's lymphoma (LGNHL), nine acute myeloid leukemia (AML), o...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703034

    authors： Olivieri A,Capelli D,Montanari M,Brunori M,Massidda D,Poloni A,Lucesole M,Centurioni R,Candela M,Masia MC,Tonnini C,Leoni P

    更新日期：2001-06-01 00:00:00

  • Evaluating the association between histological manifestations of cord colitis syndrome with GVHD.

    abstract：:Cord colitis syndrome (CCS) is a recently proposed clinical entity characterized by a persistent diarrheal illness after cord blood transplantation (CBT), which is not caused by GVHD or CMV colitis. CCS is histologically characterized by chronic active colitis with granulomatous inflammation and Paneth cell metaplasia...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2013.44

    authors： Shimoji S,Kato K,Eriguchi Y,Takenaka K,Iwasaki H,Miyamoto T,Oda Y,Akashi K,Teshima T

    更新日期：2013-09-01 00:00:00

  • High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma.

    abstract：:To investigate the possibility that a hypercoagulable state develops during autologous bone marrow transplantation (BMT), we measured levels of circulating natural anticoagulants and fibrinolytic proteins before and weekly during the hospital course of 18 patients undergoing autologous BMT for Hodgkin's and non-Hodgki...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Gordon B,Haire W,Kessinger A,Duggan M,Armitage J

    更新日期：1991-12-01 00:00:00

  • Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.

    abstract：:We investigated the use of 'prophylactic' donor lymphocyte infusions (DLI) containing 1 x 107 CD3+ cells, given at 30, 60 and 90 days post-allogeneic blood and marrow transplantation (BMT), following conditioning with fludarabine 30 mg/m(2)/4 days and melphalan 70 mg/m(2)/2 days. GVHD prophylaxis consisted of cyclospo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702726

    authors： de Lima M,Bonamino M,Vasconcelos Z,Colares M,Diamond H,Zalcberg I,Tavares R,Lerner D,Byington R,Bouzas L,da Matta J,Andrade C,Carvalho L,Pires V,Barone B,Maciel C,Tabak D

    更新日期：2001-01-01 00:00:00

  • Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study.

    abstract：:Pretransplant influenza vaccination of the donor or allogeneic hematopoietic SCT (HSCT) candidate was evaluated in a randomized study. One hundred and twenty-two HSCT recipients and their donors were assigned to three randomization groups: no pretransplant vaccination (n=38), donor pretransplant vaccination (n=44) or ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/bmt.2015.47

    authors： Ambati A,Boas LS,Ljungman P,Testa L,de Oliveira JF,Aoun M,Colturato V,Maeurer M,Machado CM

    更新日期：2015-06-01 00:00:00

  • Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response.

    abstract：:Nine patients with advanced Hodgkin's lymphoma (HL) who had undergone allogeneic stem cell transplantation (allo-SCT) received donor leukocyte infusions (DLIs) for treatment of persistent or progressive disease (PD). A total of 15 DLIs were performed, with four patients receiving more than one DLI. In four patients, p...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704621

    authors： Anderlini P,Acholonu SA,Okoroji GJ,Andersson BS,Couriel DR,De Lima MJ,Donato ML,Khouri IF,Giralt SA,Ueno NT,Champlin RE

    更新日期：2004-09-01 00:00:00

  • Pneumoperitoneum without peritonitis after allogeneic peripheral blood stem cell transplantation.

    abstract：:Allogeneic blood stem cell transplantation is associated with multiple complications. We report a case of pneumoperitoneum without peritonitis associated with colonic pneumatosis in a patient who had undergone an allogeneic peripheral blood cell transplant ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701255

    authors： de Magalhaes-Silverman M,Simpson J,Ball E

    更新日期：1998-06-01 00:00:00

  • Blood and marrow transplantation in the People's Republic of China.

    abstract：:Syngeneic BMT was first performed successfully in China in 1964. In 1981, allogeneic BMT was applied in an acute leukemia patient with success. Since then, the number of BMTs has been increasing gradually, especially since the 1990s. More than 2000 stem cell transplants per year have been performed in recent years in ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.123

    authors： Wu T,Lu DP

    更新日期：2008-08-01 00:00:00

  • Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.

    abstract：:The purpose of this trial was to study feasibility and tolerance of a dose-intensive multicyclic alternating induction chemotherapy with repeated stem cell support in a series of 43 metastatic breast cancer patients. Anthracycline-naive patients (n = 21) received cyclophosphamide 2.5 g/m(2) plus doxorubicin 80 mg/m(2)...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1703125

    authors： García-Rayo S,Pérez-Calvo J,Martín-Algarra S,Martínez-Monge R,Fernández-Hidalgo O,Subirá L,Martínez-Aguillo M,Rebollo J,Azinovic I,Brugarolas A

    更新日期：2001-08-01 00:00:00